PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32048771-0	2020	Phase Ib Study of Crizotinib Plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation.	crizotinib	18-28	ALK receptor tyrosine kinase	Homo sapiens	127-130	
32048771-1	2020	LESSONS LEARNED: This study evaluating first-line crizotinib plus pembrolizumab in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) was terminated early because increased availability of second-generation ALK inhibitors resulted in difficulty identifying and accruing eligible patients.	crizotinib	50-60	ALK receptor tyrosine kinase	Homo sapiens	97-123	
32048771-1	2020	LESSONS LEARNED: This study evaluating first-line crizotinib plus pembrolizumab in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) was terminated early because increased availability of second-generation ALK inhibitors resulted in difficulty identifying and accruing eligible patients.	crizotinib	50-60	ALK receptor tyrosine kinase	Homo sapiens	125-128	
32048771-5	2020	BACKGROUND: Previous research suggests single-agent crizotinib is efficacious for the treatment of anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer (NSCLC).	crizotinib	52-62	ALK receptor tyrosine kinase	Homo sapiens	99-125	
32048771-5	2020	BACKGROUND: Previous research suggests single-agent crizotinib is efficacious for the treatment of anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer (NSCLC).	crizotinib	52-62	ALK receptor tyrosine kinase	Homo sapiens	127-130	
32048771-6	2020	METHODS: This study evaluated the safety and preliminary antitumor activity of crizotinib plus pembrolizumab as first-line therapy in patients with ALK-rearranged NSCLC.	crizotinib	79-89	ALK receptor tyrosine kinase	Homo sapiens	148-151